IDEXX Laboratories (NASDAQ:IDXX) Insider Jonathan Jay Mazelsky Sells 25,140 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) insider Jonathan Mazelsky sold 25,140 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the transaction, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. The trade was a 23.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $670.71 on Friday. The stock’s fifty day simple moving average is $544.13 and its 200 day simple moving average is $573.40. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87. The firm has a market cap of $52.84 billion, a price-to-earnings ratio of 45.23 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period in the prior year, the business posted $3.22 earnings per share. The business’s revenue was up 9.9% compared to the same quarter last year. On average, analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Morgan Stanley raised its price target on IDEXX, a potentially supportive analyst signal; the report provided here does not specify the new target. Morgan Stanley price target report
• Positive Sentiment: IDEXX’s Q3 results were described as best-in-class. The company reported EPS of $3.96, above the $3.71 consensus, and revenue of $1.21 billion, ahead of estimates and up 9.9% year over year. IDEXX Q3 results analysis
• Negative Sentiment: A Seeking Alpha article downgraded the stock, arguing that despite IDEXX’s strong business, its shares are too expensive. Valuation concerns may limit investor appetite. IDEXX valuation downgrade
• Negative Sentiment: Four directors and executives reported selling a combined 39,225 shares on November 4, worth about $27.4 million. Each reduced their reported holdings, a potential near-term sentiment headwind, though insider sales alone do not establish the reason for selling. Read More., Read More., Read More., Read More..

Hedge Funds Weigh In On IDEXX Laboratories

Institutional investors have recently bought and sold shares of the business. Aurora Investment Managers LLC. acquired a new position in IDEXX Laboratories during the 2nd quarter worth approximately $2,442,000. National Pension Service grew its position in shares of IDEXX Laboratories by 5.6% in the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after acquiring an additional 6,885 shares during the period. NewEdge Advisors LLC grew its holdings in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after purchasing an additional 5,761 shares during the period. Arizona State Retirement System lifted its position in shares of IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after buying an additional 1,074 shares during the last quarter. Finally, Howard Capital Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $1,249,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IDXX shares. Citigroup upped their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. KeyCorp began coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating for the company. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Jefferies Financial Group decreased their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $719.55.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.